Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Behind Cephalon's Numbers: a Big Cancer Bet and Signs of Skepticism
- The FDA delivered to Cephalon a letter yesterday saying it would not approve expanded indications for its pain drug Fentora until the company gave it more information on how it would prevent the drug from being abused. Even though the Fentora situation is fixable, it's just the sort of headache...
- Blog posts 2008-09-16
- Cephalon: Damn the Torpedoes! We're Raising Prices!
- A corporate strategy question for you about Cephalon: Your industry is unpopular because of its rising prices. Your company's marketing is under the control of the U.S. Department of Justice due to illegal off-label sales. One of your best-known brands is already facing generic competition, and one of your best-selling...
- Blog posts 2008-11-18
- Generics Threaten Drugmaker Cephalon's Success
- Biotechnology watchers are measuring success at Cephalon on how quickly the drugmaker can convert patients on its soon-to-go generic blockbuster Provigil to regular users of its narcoleptic successor Nuvigil. As Jim Edwards at BNET Pharma astutely pointed out exactly one year ago, however, competition also threatens to derail...
- Blog posts 2009-09-21
Additional Resources
- Cephalon's Nuvigil Test Included "Vacation" in France
- Cephalon will ask the FDA to approve its sleep drug Nuvigil for "Eastbound" jet lag. Not Westbound. Eastbound, the company says. Turns out Cephalon flew 427 adults from the East Coast of the U.S. to France to test the drug. by Jim Edwards
- Blog posts 2009-07-01
- Cephalon Q2: Not Taking Nuvigil to Stay Awake Yet? You Will Be, Company Believes
- Cephalon is in the middle of a titanic struggle to move as many patients off its Provigil wakefulness drug onto its new brand, Nuvigil, which it just launched. Provigil goes off-patent sometime between now and April 2012, sooner if the FTC prevails in its anti pay-for-delay suit against the company....
- Blog posts 2009-08-06
- Cephalon, Inc. Q2 2008 Earnings Call
- Question-and-Answer SessionThe question and answer session will be conducted electronically. [Operator Instructions]. We will pause just a moment. We'll take our first question from Jim Birchenough with Lehman Brothers. Jim Birchenough - Lehman Brothers Hi, guys. Congratulations on the quarter. I want to start-off with a big picture question...
- Earnings calls 2008-07-29
- Cephalon, Inc., Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. And we will first go to Chris Schott from J.P. Morgan. Chris Schott - J.P. Morgan Great. Thanks. Just a couple of questions. Maybe if Frank, start by talking a little bit about the kind of M&A environment you are...
- Earnings calls 2009-02-12
- Cephalon Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator We will take our first question from Jim Birchenough with Barclays. Jim Birchenough - Barclays Just wondering on the PROVIGIL number for the quarter, it was down 10%. I'm having trouble reconciling that with the price increase and what seemed to be relatively flat volume trends. Could...
- Earnings calls 2009-05-05
- Cephalon Q4 2006 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. And we will take our first question from Greg Gilbert with Merrill Lynch. Greg Gilbert - Merrill Lynch Thanks. Good afternoon. Frank, I bet your wife didn't think she has much influence on the timing of these events. Frank Baldino ...
- Earnings calls 2007-02-12
- Our Favorite Drug Company Conference Call Tap Dancers
- Drug company conference calls with Wall Street are often dull or baffling -- a fast tide of numbers and facts extracted by spreadsheet jocks. But they're often the only chance we have to hear CEOs and other senior execs talking without the benefit of prepared remarks. Every once in while...
- Blog posts 2008-11-13
- Cephalon Inc. Q3 2008 Earnings Conference Call Transcript
- Question-and-Answer SessionThank you. [Operator Instructions]. We will take our first question from David Buck with Buckingham Research. David Buck - Buckingham Research Group Yes, thanks for taking the question. Just a couple. First on 2009, Frank, you mentioned the potential for promotional claims for individual. Is there potential... the...
- Earnings calls 2008-10-28
- Barrier announces stock offering and U.S. BioDefense signs agreement with NYSE listed $4 billion biomedical company.
- M2 PRESSWIRE-10 February 2005-FNWU: Barrier announces stock offering and U.S. BioDefense signs agreement with NYSE listed $4 billion biomedical companyC1994-2005 M2 COMMUNICATIONS LTD RDATE:02102005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Cephalon Inc....
- Research articles 2005-02-10
- << Previous
- page 1 of 1
- Next >>
